Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veltuzumab in Chronic ITP
NCT00547066Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Nov 2007
- Primary completion
- Nov 2011
- Modality
- IgG Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of veltuzumab, sponsored by Gilead Sciences. Started Nov 2007; status: terminated.
02
Drugs
veltuzumab
Beyond the preview
Go deeper on NCT00547066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00547066.